Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Stock to Watch: Rigel Pharmaceuticals Down 6.6% (RIGL)
Comtex SmarTrend(R) - Wed May 07, 12:45PM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's worst performing low-priced stocks, down 6.6% to $2.82 on 1.1x average daily volume. Rigel Pharmaceuticals has traded 833,000 shares thus far today, vs. average volume of 771,000 shares per day. The stock has underperformed the Dow (-6.6% to the Dow's 0.6%) and underperformed the S&P 500 (-6.6% to the S&P's 0.3%) during today's trading.
Rigel Announces First Quarter 2014 Financial Results
PR Newswire - Wed May 07, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014.
Rigel Announces Webcast of Investor Day on May 6, 2014
PR Newswire - Wed Apr 30, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 p.m. E.T. in New York City. Rigel management will provide an overview of the company's product portfolio and discuss future strategy.
Is Rigel Pharmaceuticals (RIGL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:46AM CDT
Rigel Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Health Care Sector Stocks under Review -- Research on Sanofi, Impax Laboratories, Keryx Biopharma, and Rigel Pharma
PR Newswire - Tue Apr 08, 12:59PM CDT
The trading session on Monday, April 07, 2014 ended on a lower note as the S&P 500 finished the session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at 4,079.75, down 1.16%. The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 664.68, down 1.06%, and the same has declined 2.85% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free technical research on SNY, IPXL, KERX and RIGL can be downloaded upon signing up at:
Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
PR Newswire - Wed Mar 19, 7:41AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the last one month. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded upon signing up at:
Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 4:15PM CDT
The negativity continued on Wall Street and with the broad-based S&P 500 today following two economic reports that came in weaker than expected. First, the Producers Price Index for February fell 0.1% against expectations for a rise of...
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Rigel (RIGL) Worth Watching: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:46AM CST
Rigel was a big mover last session, as the company saw its shares rise over 10% on the day.
Why Rigel Pharmaceuticals, Inc. Shares Popped
Alex Planes, The Motley Fool - Motley Fool - Thu Mar 06, 12:50PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rigel Pharmaceuticals are trading about...
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Rigel Announces Publication of R118 AMPK Activator Research
PR Newswire - Thu Mar 06, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation...", provides strong preclinical evidence that R118 may be useful in treating peripheral artery disease (PAD), a chronic and progressive vascular disease effecting nearly 5% of the population over the age of 50, and related metabolic disorders. This publication extends work from a previous Rigel publication on the mechanism and impact of AMPK activation. The Company also announced that it has commenced Phase 1 clinical studies with R118 as a potential treatment for Intermittent Claudication (IC), a painful and debilitating outcome of PAD.
Stock to Watch: Rigel Pharmaceuticals Up 6.8% (RIGL)
Comtex SmarTrend(R) - Wed Mar 05, 11:40AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.8% to $3.95 on 2.5x average daily volume. Rigel Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 703,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's -0.2%) and outperformed the S&P 500 (6.8% to the S&P's -0.0%) during today's trading.
Rigel Pharmaceuticals posts lower net loss of USD89.0m in 2013
M2 - Wed Mar 05, 6:21AM CST
Drug company Rigel Pharmaceuticals (NasdaqGS:RIGL) on Tuesday reported a net loss of USD89.0m (USD1.02 per basic and diluted share) for the year ended 31 December 2013.
Rigel Announces Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Tue Mar 04, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Rigel Announces Participation at Two Investor Conferences
PR Newswire - Thu Feb 27, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows:
Rigel Pharmaceuticals Up 6.1%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Mon Feb 24, 10:12AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.1% to $3.66 on 1.8x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 1.1 million shares, vs. average volume of 615,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.9%) and outperformed the S&P 500 (6.1% to the S&P's 0.9%) during today's trading.